• Je něco špatně v tomto záznamu ?

Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study

Y. Prysiazhniuk, A. Server, H. Leske, Ø. Bech-Aase, E. Helseth, RS. Eijgelaar, E. Fuster-García, P. Brandal, A. Bjørnerud, J. Otáhal, J. Petr, W. Nordhøy

. 2024 ; 6 (1) : vdae113. [pub] 20240705

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018273

BACKGROUND: Evaluation of molecular markers (IDH, pTERT, 1p/19q codeletion, and MGMT) in adult diffuse gliomas is crucial for accurate diagnosis and optimal treatment planning. Dynamic Susceptibility Contrast (DSC) and Arterial Spin Labeling (ASL) perfusion MRI techniques have both shown good performance in classifying molecular markers, however, their performance has not been compared side-by-side. METHODS: Pretreatment MRI data from 90 patients diagnosed with diffuse glioma (54 men/36 female, 53.1 ± 15.5 years, grades 2-4) were retrospectively analyzed. DSC-derived normalized cerebral blood flow/volume (nCBF/nCBV) and ASL-derived nCBF in tumor and perifocal edema were analyzed in patients with available IDH-mutation (n = 67), pTERT-mutation (n = 39), 1p/19q codeletion (n = 33), and MGMT promoter methylation (n = 31) status. Cross-validated uni- and multivariate logistic regression models assessed perfusion parameters' performance in molecular marker detection. RESULTS: ASL and DSC perfusion parameters in tumor and edema distinguished IDH-wildtype (wt) and pTERT-wt tumors from mutated ones. Univariate classification performance was comparable for ASL-nCBF and DSC-nCBV in IDH (maximum AUROCC 0.82 and 0.83, respectively) and pTERT (maximum AUROCC 0.70 and 0.81, respectively) status differentiation. The multivariate approach improved IDH (DSC-nCBV AUROCC 0.89) and pTERT (ASL-nCBF AUROCC 0.8 and DSC-nCBV AUROCC 0.86) classification. However, ASL and DSC parameters could not differentiate 1p/19q codeletion or MGMT promoter methylation status. Positive correlations were found between ASL-nCBF and DSC-nCBV/-nCBF in tumor and edema. CONCLUSIONS: ASL is a viable gadolinium-free replacement for DSC for molecular characterization of adult diffuse gliomas.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018273
003      
CZ-PrNML
005      
20241016081828.0
007      
ta
008      
241008s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/noajnl/vdae113 $2 doi
035    __
$a (PubMed)39036439
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Prysiazhniuk, Yeva $u Department of Pathophysiology, Second Faculty of Medicine, Charles University, Prague, The Czech Republic $1 https://orcid.org/0000000173841693
245    10
$a Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study / $c Y. Prysiazhniuk, A. Server, H. Leske, Ø. Bech-Aase, E. Helseth, RS. Eijgelaar, E. Fuster-García, P. Brandal, A. Bjørnerud, J. Otáhal, J. Petr, W. Nordhøy
520    9_
$a BACKGROUND: Evaluation of molecular markers (IDH, pTERT, 1p/19q codeletion, and MGMT) in adult diffuse gliomas is crucial for accurate diagnosis and optimal treatment planning. Dynamic Susceptibility Contrast (DSC) and Arterial Spin Labeling (ASL) perfusion MRI techniques have both shown good performance in classifying molecular markers, however, their performance has not been compared side-by-side. METHODS: Pretreatment MRI data from 90 patients diagnosed with diffuse glioma (54 men/36 female, 53.1 ± 15.5 years, grades 2-4) were retrospectively analyzed. DSC-derived normalized cerebral blood flow/volume (nCBF/nCBV) and ASL-derived nCBF in tumor and perifocal edema were analyzed in patients with available IDH-mutation (n = 67), pTERT-mutation (n = 39), 1p/19q codeletion (n = 33), and MGMT promoter methylation (n = 31) status. Cross-validated uni- and multivariate logistic regression models assessed perfusion parameters' performance in molecular marker detection. RESULTS: ASL and DSC perfusion parameters in tumor and edema distinguished IDH-wildtype (wt) and pTERT-wt tumors from mutated ones. Univariate classification performance was comparable for ASL-nCBF and DSC-nCBV in IDH (maximum AUROCC 0.82 and 0.83, respectively) and pTERT (maximum AUROCC 0.70 and 0.81, respectively) status differentiation. The multivariate approach improved IDH (DSC-nCBV AUROCC 0.89) and pTERT (ASL-nCBF AUROCC 0.8 and DSC-nCBV AUROCC 0.86) classification. However, ASL and DSC parameters could not differentiate 1p/19q codeletion or MGMT promoter methylation status. Positive correlations were found between ASL-nCBF and DSC-nCBV/-nCBF in tumor and edema. CONCLUSIONS: ASL is a viable gadolinium-free replacement for DSC for molecular characterization of adult diffuse gliomas.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Server, Andres $u Section of Neuroradiology, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000258844527
700    1_
$a Leske, Henning $u Department of Pathology, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000230578730
700    1_
$a Bech-Aase, Øystein $u Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
700    1_
$a Helseth, Eirik $u Department of Neurosurgery, Oslo University Hospital, Oslo, Norway $u Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000157586485
700    1_
$a Eijgelaar, Roelant Sjouke $u Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, The Netherlands $1 https://orcid.org/0000000217654444
700    1_
$a Fuster-García, Elies $u Biomedical Data Science Laboratory, Instituto Universitario de Tecnologías de la Información y Comunicaciones, Universitat Politècnica de València, València, Spain $1 https://orcid.org/0000000207168960
700    1_
$a Brandal, Petter $u Department of Oncology, Oslo University Hospital, Oslo, Norway $u Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/000000030259495X
700    1_
$a Bjørnerud, Atle $u Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway $u Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000234863141
700    1_
$a Otáhal, Jakub $u Department of Pathophysiology, Second Faculty of Medicine, Charles University, Prague, The Czech Republic $1 https://orcid.org/0000000159445803 $7 xx0105144
700    1_
$a Petr, Jan $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $u Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands $1 https://orcid.org/0000000232016002 $7 xx0143826
700    1_
$a Nordhøy, Wibeke $u Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000312324187
773    0_
$w MED00207627 $t Neuro-oncology advances $x 2632-2498 $g Roč. 6, č. 1 (2024), s. vdae113
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39036439 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081823 $b ABA008
999    __
$a ok $b bmc $g 2196507 $s 1230224
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 6 $c 1 $d vdae113 $e 20240705 $i 2632-2498 $m Neuro-oncology advances $n Neurooncol Adv $x MED00207627
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Možnosti archivace